Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma (Nasdaq: CNTB) said it has completed enrollment in its Phase 2 Seabreeze STAT Asthma study of rademikibart (adjunct to standard of care) for acute asthma exacerbations in patients with type 2 inflammation; it enrolled 160 participants. The company expects topline data in early September 2026, plans to complete COPD enrollment this month, and aims to align on a Phase 3 program with the FDA later this year.
How this was made
The 30-second read
Why it matters
This release lowers operational uncertainty (asthma enrollment completed) and provides a forward-looking catalyst schedule (asthma topline early September 2026; COPD topline soon after; Phase 3 alignment with FDA later this year).
Market read
For CNTB, the actionable element is the next data timeline: enrollment completion plus an early-September topline target can shift probability-weighted expectations ahead of efficacy/safety results.
What to watch
Key risk remains whether the primary endpoint (treatment failure over 28 days) and Week-1 FEV1 show differentiation; also, FDA alignment for Phase 3 could change study design expectations.
Background
Connect Biopharma is running its Seabreeze STAT Phase 2 program for rademikibart (IL-4Rα antibody) in acute exacerbations of asthma and COPD, with eosinophil-enriched inclusion criteria.
Ticker impact
Connect Biopharma says it completed enrollment in its Phase 2 Seabreeze STAT Asthma study of rademikibart and expects topline data in early September 2026.
Bias toward modest positive near-term sentiment into the early-September topline window, with volatility likely around any subsequent FDA/Phase 3 alignment updates.
The article discloses a concrete operational milestone (enrollment completion) plus a specific timing target for topline data and planned FDA alignment, which can re-rate probability-weighted outcomes for a clinical-stage biotech.
Market effects
Reinforces investor focus on IL-4/IL-13 pathway biologics for acute exacerbations in asthma/COPD and the importance of eosinophil-enriched populations.
Limited direct regional impact; primarily US biotech sentiment with global enrollment execution.
Global trial enrollment completion can support broader confidence in development timelines, but commercial impact depends on Phase 3 outcomes.
Counterpoint
Enrollment completion is an execution milestone, not efficacy/safety data; the stock may already price in timeline progress, leaving upside capped until topline results.
Key entities
- companyConnect Biopharma Holdings Limited
Clinical-stage biopharmaceutical company advancing rademikibart; announced completion of enrollment in Seabreeze STAT Asthma Phase 2.
- drug_candidaterademikibart
Fully human monoclonal antibody targeting IL-4 receptor alpha (IL-4Rα) for acute exacerbations in asthma/COPD.
- clinical_trialSeabreeze STAT Asthma
Phase 2 randomized, double-blind, placebo-controlled study; enrollment completed (160 participants) with topline expected early September 2026.
- clinical_trialSeabreeze STAT COPD
Phase 2 study expected to complete enrollment this month; topline expected soon after asthma readout.
